Clinical Trials Logo

Filter by:
NCT ID: NCT05287750 Recruiting - Brain Tumor Clinical Trials

Brain Diseases on 7.0T Magnetic Resonance Imaging

Start date: January 1, 2022
Phase: N/A
Study type: Interventional

This clinical trial studies the use of 7-Tesla (7T)and 3T magnetic resonance imaging (MRI) in detecting brain diseases. 7T MRI has increased detection sensitivity, including more accurate lesion delineation, higher inter-rater agreement. Diagnostic procedures such as 7T MRI may help ultimately improved diagnostic and therapies confidence to inform decision making than standard 3T MRI.

NCT ID: NCT05287386 Recruiting - Clinical trials for Advanced Non-Small Cell Lung Cancer

A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy

Start date: January 21, 2022
Phase: Phase 2
Study type: Interventional

This study is a prospective single-arm phase II clinical study. Advanced non-small cell lung cancer patients with FGFR 1-3 alterations (including but not limited to FGFR amplification, rearrangement/fusion, mutation, etc.) who have failed standard therapy will be enrolled in this study once they have signed the informed consent form (ICF) and been identified as eligible in screening.

NCT ID: NCT05287165 Recruiting - Clinical trials for Advanced Solid Tumors

Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms

Start date: March 10, 2022
Phase: Early Phase 1
Study type: Interventional

This is a open-label, single center to determine the efficacy and safety of IM96 CAR-T cells in Patients With Advanced Digestive System Neoplasms

NCT ID: NCT05286957 Recruiting - NSCLC Clinical Trials

MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC

Seagull
Start date: June 20, 2022
Phase: Phase 2
Study type: Interventional

Seagull is a phase Ⅱ study designed to investigate the efficacy and safety of MRD-guided adjuvant tislelizumab and chemotherapy vs adjuvant tislelizumab and chemotherapy in patients with resectable NSCLC

NCT ID: NCT05286710 Recruiting - Clinical trials for Deep Vein Thrombosis

Rheolytic Thrombectomy For Acute Deep Vein Thrombosis Of Whole Lower Limb

Start date: October 26, 2022
Phase: N/A
Study type: Interventional

Ipsilateral popliteal venous the most common access for pharmacomechanical thrombectomy (PMT) in the treatment of acute deep venous thrombosis (DVT), but the result was not satisfactory. The investigators adjust the access to improve the thrombus clearance rate and reduce the incidence of post-thrombotic syndrome (PTS).

NCT ID: NCT05286645 Recruiting - Depressive Disorder Clinical Trials

Intervention Effect of High Definition Transcranial Direct Current Stimulation (HD-tDCS) on Depressive Disorder

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

To investigate the intervention effect of high definition transcranial direct current stimulation (HD-tDCS) on suicidal ideation and somatic symptoms in patients with depressive disorder and its underlying neural mechanism by MRI.

NCT ID: NCT05286099 Recruiting - Clinical trials for Hepatocellular Carcinoma

The Surveillance of Hepatocellular Carcinoma

Start date: January 15, 2022
Phase:
Study type: Observational

Early detection of hepatocellular carcinoma is vita to the prognosis of patient. In this study, the occurrence and development of liver cancer were supervised by imaging examination, and the dysplastic nodules will be distinguished from early hepatocellular carcinoma through macro-imaging and micro-pathological features.

NCT ID: NCT05285124 Recruiting - Clinical trials for Disorder of Consciousness

HD-tDCS Combined With Circadian Rhythm Reconstruction and Micro Expression Changes on Consciousness Recovery in Patients With Chronic Disturbance of Consciousness

HD-tDCS
Start date: July 1, 2021
Phase: N/A
Study type: Interventional

The circadian rhythm characteristics of sleep cycle and neuroendocrine in patients with chronic disorder of consciousness show different degrees of disorder, and the relationship between this disorder and consciousness level is unclear.The researchers used HD-tDCS to treat patients with chronic disturbance of consciousness who intervened in circadian rhythm, and used a variety of methods such as EEG, fMRI, protein metabolism, ERP and micro-expression to explore the mechanism of improving the state of consciousness of HD-DCS and the relationship between circadian rhythm and patients' consciousness level

NCT ID: NCT05284994 Recruiting - Clinical trials for Nonsmall-cell Lung Cancer

TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung Cancer

Start date: March 11, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

TQ-B3525 tablet is a new α/δ dual inhibitor phosphatidylinositol 3-kinase inhibitor developed by Chia Tai Tianqing pharmaceutical Group Co., Ltd. It can overcome the drug resistance problem caused by the up-regulation of phosphatidylinositol 3-kinase α subunit activity caused by the single inhibition of phosphatidylinositol 3-kinase δ subunit. This study is a single-arm, open-label, multi-cohort, multi-center clinical study of the safety and efficacy of TQ-B3525 tablets combined with osimertinib in subjects with advanced non-small cell lung cancer, aiming to evaluate TQ-B3525 tablets combined with osimertinib, the safety, tolerability, and efficacy of the treatment of patients with advanced non-small cell lung cancer who have failed epidermal growth factor receptor inhibitor therapy, while exploring the efficacy, resistance mechanism, and safety in the dose escalation phase biomarkers.

NCT ID: NCT05284942 Recruiting - Clinical trials for Langerhans Cell Histiocytosis

Central China Rosai-Dorfman Disease Registry

CCR-DDR
Start date: October 1, 2011
Phase: Phase 4
Study type: Interventional

This is a research study among patients with Rosai-Dorfman disease.